The Modesto Bee Local Stock Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Roche Holding AG Basel American Depositary Shares (OP: RHHBY)
64.71 USD  +1.18 (+1.86%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News Research
Blog posts about Roche Holding AG Basel American Depositary Shares
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Gen-Probe’s EPS Trounces, Net Slips
February 15, 2012
Diagnostic products maker Gen-Probe’s (NASDAQ:GPRO) fourth-quarter fiscal 2011 adjusted (excluding one-time charges) earnings of 72 cents a share topped the Zacks Consensus Estimate by 4 cents while... Read More
category RHHBY , External Research , Contributor , and 5 more.
from DailyMarkets.com
Alnylam Delivers In-Line Numbers
February 13, 2012
Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) fourth quarter 2011 loss of 33 cents per share was in line with the Zacks Consensus Estimate. The loss was however wider than the year-ago loss of 16 cents... Read More
category RHHBY , External Research , Contributor , and 5 more.
from DailyMarkets.com
InterMune Widens Loss, Sales Dip
February 10, 2012
InterMune Inc. (NASDAQ:ITMN) posted fourth-quarter adjusted loss per share of 69 cents, wider than the year-ago adjusted loss per share of 42 cents, afflicted by lower revenues and higher operating... Read More
category ITMN , RHHBY , Stocks , and 2 more.
from DailyMarkets.com
Speedy Review For Roche Drug
February 09, 2012
Roche Holdings Ltd. (RHHBY) recently announced that its Biologics License Application (BLA) for pertuzumab has been accepted by the US Food and Drug Administration (FDA) for review. The regulatory body... Read More
category RHHBY , Stocks , GSK , and 2 more.
from DailyMarkets.com
Life Technologies Beats, Profit Up
February 08, 2012
Life Technologies Corporation (LIFE) reported an adjusted EPS of $1.06 in the fourth quarter of fiscal 2011, beating both the Zacks Consensus Estimate of $1.03 and the year-ago quarter’s adjusted EPS... Read More
category RHHBY , ILMN , Stocks , and 3 more.
from DailyMarkets.com
Genomic Misses, Grows Annually
February 07, 2012
Genomic Health (NASDAQ:GHDX) reported an EPS of 8 cents in the fourth quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, but higher than 6 cents earned in the year-ago period. For the... Read More
category RHHBY , ILMN , GHDX , and 4 more.
from DailyMarkets.com
Earnings Preview: Life Technologies
February 06, 2012
Global biotechnology company, Life Technologies (LIFE) is scheduled to report its fourth quarter and fiscal 2011 results on Tuesday, February 7, 2012, after market close. The company is expected to... Read More
category RHHBY , ILMN , Stocks , and 3 more.
from DailyMarkets.com
Roche Beats; Optimistic About 2012
February 02, 2012
Roche Holdings Ltd.’s (RHHBY) fiscal 2011 earnings per share came in at $3.48, compared with $3.07 reported in the year-ago period. Earnings came in ahead of the Zacks Consensus Estimate of $3.31.... Read More
category RHHBY , ILMN , Stocks , and 2 more.
from DailyMarkets.com
Merck Beats On EPS, Guides In-Line
February 02, 2012
Merck & Co. (NYSE:MRK) reported fourth quarter 2011 earnings per share (excluding special items) of 97 cents, a couple of cents above the Zacks Consensus Estimate and 10.2% above the year-ago earnings.... Read More
category RHHBY , jnj , MRK , and 3 more.
from DailyMarkets.com
Roche Brings Another Drug To Market
February 01, 2012
Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration (FDA) has approved its skin cancer drug Erivedge (vismodegib) for the treatment of patients with advanced basal... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
EPS Beat For Biogen; Outlook Weak
January 31, 2012
Biogen Idec (NASDAQ:BIIB) reported fourth-quarter earnings per share of $1.51, well above the Zacks Consensus Estimate of $1.46 and the year-ago earnings of $1.41. Fourth quarter results were boosted... Read More
category NVS , RHHBY , ELN , and 4 more.
from DailyMarkets.com
Roche Aims For Illumina
January 25, 2012
Roche Holdings Ltd. (RHHBY) recently announced that it has placed a bid to acquire all the outstanding shares of Illumina Inc. (NASDAQ:ILMN). Roche’s offer of $44.50 per share (aggregate value $5.7... Read More
category RHHBY , ILMN , Stocks , and 2 more.
from DailyMarkets.com
LabCorp Offers New Test
January 20, 2012
Laboratory Corporation of America Holdings (NYSE:LH) has launched Roma (Risk of Ovarian Malignancy Algorithm) risk assessment tool to evaluate whether an ovarian mass is at high or low likelihood of... Read More
category LH , RHHBY , DGX , and 4 more.
from DailyMarkets.com
Gilead Clinches Pharmasset Buy
January 19, 2012
Gilead Sciences, Inc. (NASDAQ:GILD) announced recently that it has completed its previously announced agreement to buy Pharmasset, Inc, a maker of drugs for the treatment of chronic hepatitis C virus... Read More
category RHHBY , INHX , External Research , and 6 more.
from DailyMarkets.com
Biosimilars: The Next Big Thing
January 13, 2012
As a large number of branded biopharmaceuticals/biologics are slated to lose patent protection in the US and other markets, generic companies like Hospira, Inc. (NYSE:HSP), Teva Pharmaceuticals... Read More
category RHHBY , TEVA , External Research , and 9 more.
from DailyMarkets.com
Vivus’ Obesity Drug Label Modified
January 12, 2012
Vivus Inc. (NASDAQ:VVUS) recently announced that women of childbearing potential can now use its obesity candidate Qnexa. The US Food and Drug Administration (FDA) has asked the company to remove the... Read More
category RHHBY , Stocks , GSK , and 3 more.
from DailyMarkets.com
Roche-Xenon Agree To Join Forces
January 10, 2012
Roche Holdings Ltd.’s (RHHBY) subsidiary, Genentech, and Xenon Pharmaceuticals Inc. recently announced a collaboration for the discovery and development of compounds and companion diagnostics for the... Read More
category RHHBY , EVTCY , MRK , and 3 more.
from DailyMarkets.com
Regeneron Settles Dispute
January 04, 2012
Recently, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reached a non-exclusive license and partial settlement agreement with Genentech, Inc. {a wholly owned subsidiary of Roche (RHHBY)} regarding the... Read More
category NVS , RHHBY , REGN , and 3 more.
from DailyMarkets.com
Alnylam States Preclinical Data
December 30, 2011
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel... Read More
category RHHBY , MDT , External Research , and 6 more.
from DailyMarkets.com
Pipeline Setback For Glaxo
December 15, 2011
GlaxoSmithKline (NYSE:GSK) recently announced disappointing results from a phase III study TEACH (Tykerb Evaluation After Chemotherapy) of Tykerb (lapatinib) as a delayed adjuvant monotherapy for... Read More
category RHHBY , Stocks , GSK , and 2 more.
from DailyMarkets.com
Micromet’s Blinatumomub Data At ASH
December 13, 2011
Micromet Inc. (NASDAQ:MITI) recently presented encouraging data from a mid-stage study of its lead pipeline candidate blinatumomab in adults suffering from relapsed or refractory B-precursor acute... Read More
category AZN , RHHBY , External Research , and 7 more.
from DailyMarkets.com
Positive Data On Novartis’ Afinitor
December 12, 2011
Novartis’ (NYSE:NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an... Read More
category AZN , RHHBY , External Research , and 5 more.
from DailyMarkets.com
Positive Data For Roche’s Drug
December 09, 2011
Roche Holdings Ltd. (RHHBY) recently reported positive data from a late-stage study, CLEOPATRA, which investigated a combination treatment involving pertuzumab and Herceptin (trastuzumab). The study... Read More
category RHHBY , Stocks , GSK , and 2 more.
from DailyMarkets.com
Dendreon To Sell Victrelis Rights
December 08, 2011
Dendreon Corporation (NASDAQ:DNDN), which is currently going through a rough patch, tried a hand at improving its financial position. This time, Dendreon has entered into a deal to sell its royalty... Read More
category RHHBY , MRK , Stocks , and 3 more.
from DailyMarkets.com
Alnylam Completes Trial Enrollment
December 01, 2011
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic... Read More
category RHHBY , MDT , External Research , and 7 more.
from DailyMarkets.com
Alnylam Reveals ALNTTR01 Trial Data
November 25, 2011
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically... Read More
category RHHBY , MDT , External Research , and 7 more.
from DailyMarkets.com
Gilead To Buy Pharmasset For $11B
November 22, 2011
Gilead Sciences, Inc. (NASDAQ:GILD) announced recently that it has entered into a definitive agreement to acquire Pharmasset, Inc. (NASDAQ:VRUS), a maker of drugs for the treatment of chronic hepatitis... Read More
category RHHBY , VRUS , jnj , and 4 more.
from DailyMarkets.com
Roche’s Avastin Loses FDA’s Support
November 21, 2011
Roche Holdings Ltd. (RHHBY) has been a regular topic of discussion of late, but this time it is in the news not for positive reasons. The company announced that the US Food and Drug Administration... Read More
category RHHBY , MKGAF , Stocks , and 3 more.
from DailyMarkets.com
News Links 11-18-11
November 18, 2011
from Wall Street Greek
Roche Eyes Cancer Drug Approval
November 14, 2011
Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for vismodegib for review. The company is seeking approval of... Read More
category RHHBY , Stocks , External Research , and 2 more.
from DailyMarkets.com
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here